- Investing.com
Metrics to compare | COCP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCOCPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.7x | −1.0x | −0.5x | |
PEG Ratio | −0.03 | −0.13 | 0.00 | |
Price/Book | 3.7x | 1.8x | 2.6x | |
Price / LTM Sales | 68.0x | 22.5x | 3.1x | |
Upside (Analyst Target) | - | 354.6% | 55.1% | |
Fair Value Upside | Unlock | −5.5% | 7.2% | Unlock |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.